{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T05:05:55Z","timestamp":1773464755228,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["IITP-2025-RS-2023-00260175"],"award-info":[{"award-number":["IITP-2025-RS-2023-00260175"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2024-00345226"],"award-info":[{"award-number":["RS-2024-00345226"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"DOI":"10.1186\/s12859-025-06125-0","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T09:58:57Z","timestamp":1746439137000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PathNetDRP: a novel biomarker discovery framework using pathway and protein\u2013protein interaction networks for immune checkpoint inhibitor response prediction"],"prefix":"10.1186","volume":"26","author":[{"given":"Dohee","family":"Lee","sequence":"first","affiliation":[]},{"given":"Jaegyoon","family":"Ahn","sequence":"additional","affiliation":[]},{"given":"Jonghwan","family":"Choi","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"issue":"3","key":"6125_CR1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133\u201350.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"6125_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50(12):1\u201311.","journal-title":"Exp Mol Med"},{"issue":"4","key":"6125_CR3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E. Nivolumab in previously untreated melanoma without braf mutation. N Engl J Med. 2015;372(4):320\u201330.","journal-title":"N Engl J Med"},{"key":"6125_CR4","doi-asserted-by":"publisher","first-page":"102499","DOI":"10.1016\/j.ctrv.2022.102499","volume":"113","author":"DC Ziogas","year":"2023","unstructured":"Ziogas DC, Theocharopoulos C, Koutouratsas T, Haanen J, Gogas H. Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome? Cancer Treat Rev. 2023;113:102499.","journal-title":"Cancer Treat Rev"},{"issue":"21","key":"6125_CR5","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018\u201328.","journal-title":"N Engl J Med"},{"issue":"26","key":"6125_CR6","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D. Pd-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509\u201320.","journal-title":"N Engl J Med"},{"key":"6125_CR7","doi-asserted-by":"crossref","unstructured":"Shum B, Larkin J, Turajlic S. Predictive biomarkers for response to immune checkpoint inhibition. In: Seminars in Cancer Biology, vol. 79, Amsterdam: Elsevier; 2022. pp. 4\u201317","DOI":"10.1016\/j.semcancer.2021.03.036"},{"issue":"10064","key":"6125_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67\u201376.","journal-title":"Lancet"},{"issue":"1","key":"6125_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","volume":"21","author":"P Schmid","year":"2020","unstructured":"Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Di\u00e9ras V, Henschel V, Molinero L, Chui SY. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (impassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44\u201359.","journal-title":"Lancet Oncol"},{"issue":"1","key":"6125_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","volume":"5","author":"NJ Llosa","year":"2015","unstructured":"Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5(1):43\u201351.","journal-title":"Cancer Discov"},{"issue":"8","key":"6125_CR11","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V. Ifn-$$\\gamma$$-related mrna profile predicts clinical response to pd-1 blockade. J Clin Investig. 2017;127(8):2930\u201340.","journal-title":"J Clin Investig"},{"issue":"3","key":"6125_CR12","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","volume":"184","author":"K Litchfield","year":"2021","unstructured":"Litchfield K, Reading JL, Puttick C, Thakkar K, Abbosh C, Bentham R, Watkins TB, Rosenthal R, Biswas D, Rowan A. Meta-analysis of tumor-and t cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell. 2021;184(3):596\u2013614.","journal-title":"Cell"},{"key":"6125_CR13","doi-asserted-by":"crossref","unstructured":"Harper J, Sainson RC. Regulation of the anti-tumour immune response by cancer-associated fibroblasts. In: Seminars in Cancer Biology, vol. 25, Elsevier; 2014. p. 69\u201377","DOI":"10.1016\/j.semcancer.2013.12.005"},{"issue":"1","key":"6125_CR14","doi-asserted-by":"publisher","first-page":"1747340","DOI":"10.1080\/2162402X.2020.1747340","volume":"9","author":"AR Dancsok","year":"2020","unstructured":"Dancsok AR, Gao D, Lee AF, Steigen SE, Blay J-Y, Thomas DM, Maki RG, Nielsen TO, Demicco EG. Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas. Oncoimmunology. 2020;9(1):1747340.","journal-title":"Oncoimmunology"},{"issue":"10","key":"6125_CR15","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B. Signatures of t cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550\u20138.","journal-title":"Nat Med"},{"issue":"10","key":"6125_CR16","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/s41591-018-0157-9","volume":"24","author":"N Auslander","year":"2018","unstructured":"Auslander N, Zhang G, Lee JS, Frederick DT, Miao B, Moll T, Tian T, Wei Z, Madan S, Sullivan RJ. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat Med. 2018;24(10):1545\u20139.","journal-title":"Nat Med"},{"issue":"5","key":"6125_CR17","doi-asserted-by":"publisher","first-page":"104228","DOI":"10.1016\/j.isci.2022.104228","volume":"25","author":"Y Kang","year":"2022","unstructured":"Kang Y, Vijay S, Gujral TS. Deep neural network modeling identifies biomarkers of response to immune-checkpoint therapy. Iscience. 2022;25(5):104228.","journal-title":"Iscience."},{"issue":"1","key":"6125_CR18","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1038\/s41467-022-31535-6","volume":"13","author":"J Kong","year":"2022","unstructured":"Kong J, Ha D, Lee J, Kim I, Park M, Im S-H, Shin K, Kim S. Network-based machine learning approach to predict immunotherapy response in cancer patients. Nat Commun. 2022;13(1):3703.","journal-title":"Nat Commun"},{"issue":"2","key":"6125_CR19","doi-asserted-by":"publisher","first-page":"023","DOI":"10.1093\/bib\/bbad023","volume":"24","author":"L Zhao","year":"2023","unstructured":"Zhao L, Qi X, Chen Y, Qiao Y, Bu D, Wu Y, Luo Y, Wang S, Zhang R, Zhao Y. Biological knowledge graph-guided investigation of immune therapy response in cancer with graph neural network. Brief Bioinform. 2023;24(2):023.","journal-title":"Brief Bioinform"},{"issue":"43","key":"6125_CR20","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"6125_CR21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41592-019-0686-2","volume":"17","author":"P Virtanen","year":"2020","unstructured":"Virtanen P, Gommers R, Oliphant TE, Haberland M, Reddy T, Cournapeau D, Burovski E, Peterson P, Weckesser W, Bright J. Scipy 1.0: fundamental algorithms for scientific computing in python. Nat Methods. 2020;17(3):261\u201372.","journal-title":"Nat Methods"},{"key":"6125_CR22","first-page":"1","volume":"7","author":"S Seabold","year":"2010","unstructured":"Seabold S, Perktold J. Statsmodels: econometric and statistical modeling with python. SciPy. 2010;7:1.","journal-title":"SciPy"},{"key":"6125_CR23","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3103\/S1066530717030048","volume":"26","author":"L Al-Labadi","year":"2017","unstructured":"Al-Labadi L, Zarepour M. Two-sample Kolmogorov-Smirnov test using a Bayesian nonparametric approach. Math Methods Statist. 2017;26:212\u201325.","journal-title":"Math Methods Statist"},{"issue":"9","key":"6125_CR24","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/j.cell.2021.03.030","volume":"184","author":"JS Lee","year":"2021","unstructured":"Lee JS, Nair NU, Dinstag G, Chapman L, Chung Y, Wang K, Sinha S, Cha H, Kim D, Schperberg AV. Synthetic lethality-mediated precision oncology via the tumor transcriptome. Cell. 2021;184(9):2487\u2013502.","journal-title":"Cell"},{"issue":"7693","key":"6125_CR25","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel Iii EE, Koeppen H, Astarita JL, Cubas R. Tgf$$\\beta$$ attenuates tumour response to pd-l1 blockade by contributing to exclusion of t cells. Nature. 2018;554(7693):544\u20138.","journal-title":"Nature"},{"issue":"4","key":"6125_CR26","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Mart\u00edn-Algarra S, Mandal R, Sharfman WH. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell. 2017;171(4):934\u201349.","journal-title":"Cell"},{"issue":"13","key":"6125_CR27","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-16-3556","volume":"77","author":"A Prat","year":"2017","unstructured":"Prat A, Navarro A, Par\u00e9 L, Reguart N, Galv\u00e1n P, Pascual T, Mart\u00ednez A, Nuciforo P, Comerma L, Alos L. Immune-related gene expression profiling after pd-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma. Can Res. 2017;77(13):3540\u201350.","journal-title":"Can Res"},{"issue":"9","key":"6125_CR28","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim ST, Cristescu R, Bass AJ, Kim K-M, Odegaard JI, Kim K, Liu XQ, Sher X, Jung H, Lee M. Comprehensive molecular characterization of clinical responses to pd-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449\u201358.","journal-title":"Nat Med"},{"issue":"2","key":"6125_CR29","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M. New response evaluation criteria in solid tumours: revised recist guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"D1","key":"6125_CR30","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P. String v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):607\u201313.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"6125_CR31","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/nar\/gkab1028","volume":"50","author":"M Gillespie","year":"2022","unstructured":"Gillespie M, Jassal B, Stephan R, Milacic M, Rothfels K, Senff-Ribeiro A, Griss J, Sevilla C, Matthews L, Gong C. The reactome pathway knowledgebase 2022. Nucleic Acids Res. 2022;50(D1):687\u201392.","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"6125_CR32","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41588-020-0687-1","volume":"52","author":"E Lakatos","year":"2020","unstructured":"Lakatos E, Williams MJ, Schenck RO, Cross WC, Househam J, Zapata L, Werner B, Gatenbee C, Robertson-Tessi M, Barnes CP. Evolutionary dynamics of neoantigens in growing tumors. Nat Genet. 2020;52(10):1057\u201366.","journal-title":"Nat Genet"},{"issue":"4","key":"6125_CR33","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ijc.32193","volume":"146","author":"M Nurmik","year":"2020","unstructured":"Nurmik M, Ullmann P, Rodriguez F, Haan S, Letellier E. In search of definitions: cancer-associated fibroblasts and their markers. Int J Cancer. 2020;146(4):895\u2013905.","journal-title":"Int J Cancer"},{"issue":"3","key":"6125_CR34","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.it.2017.12.001","volume":"39","author":"JE Boudreau","year":"2018","unstructured":"Boudreau JE, Hsu KC. Natural killer cell education and the response to infection and cancer therapy: stay tuned. Trends Immunol. 2018;39(3):222\u201339.","journal-title":"Trends Immunol"},{"key":"6125_CR35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.cellimm.2016.04.005","volume":"303","author":"CE Gallegos","year":"2016","unstructured":"Gallegos CE, Michelin S, Dubner D, Carosella ED. Immunomodulation of classical and non-classical hla molecules by ionizing radiation. Cell Immunol. 2016;303:16\u201323.","journal-title":"Cell Immunol"},{"issue":"1","key":"6125_CR36","first-page":"349575","volume":"2011","author":"A Lasfar","year":"2011","unstructured":"Lasfar A, Abushahba W, Balan M, Cohen-Solal KA. Interferon lambda: a new sword in cancer immunotherapy. J Immunol Res. 2011;2011(1):349575.","journal-title":"J Immunol Res"},{"issue":"12","key":"6125_CR37","doi-asserted-by":"publisher","first-page":"7686","DOI":"10.4049\/jimmunol.176.12.7686","volume":"176","author":"A Sato","year":"2006","unstructured":"Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T. Antitumor activity of ifn-$$\\lambda$$ in murine tumor models. J Immunol. 2006;176(12):7686\u201394.","journal-title":"J Immunol"},{"key":"6125_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/bs.ai.2015.04.001","volume":"127","author":"ED Carosella","year":"2015","unstructured":"Carosella ED, Rouas-Freiss N, Tronik-Le Roux D, Moreau P, LeMaoult J. Hla-g: an immune checkpoint molecule. Adv Immunol. 2015;127:33\u2013144.","journal-title":"Adv Immunol"},{"issue":"18","key":"6125_CR39","doi-asserted-by":"publisher","first-page":"7064","DOI":"10.1073\/pnas.0401922101","volume":"101","author":"J LeMaoult","year":"2004","unstructured":"LeMaoult J, Krawice-Radanne I, Dausset J, Carosella ED. Hla-g1-expressing antigen-presenting cells induce immunosuppressive cd4+ t cells. Proc Natl Acad Sci. 2004;101(18):7064\u20139.","journal-title":"Proc Natl Acad Sci"},{"key":"6125_CR40","doi-asserted-by":"publisher","first-page":"1165813","DOI":"10.3389\/fimmu.2023.1165813","volume":"14","author":"J Bartolome","year":"2023","unstructured":"Bartolome J, Molto C, Benitez-Fuentes JD, Fernandez-Hinojal G, Manzano A, Perez-Segura P, Mittal A, Tamimi F, Amir E, Ocana A. Prognostic value of human leukocyte antigen g expression in solid tumors: a systematic review and meta-analysis. Front Immunol. 2023;14:1165813.","journal-title":"Front Immunol"},{"issue":"10","key":"6125_CR41","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrd3810","volume":"11","author":"RJ Akhurst","year":"2012","unstructured":"Akhurst RJ, Hata A. Targeting the tgf$$\\beta$$ signalling pathway in disease. Nat Rev Drug Discovery. 2012;11(10):790\u2013811.","journal-title":"Nat Rev Drug Discovery"},{"issue":"1","key":"6125_CR42","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41698-021-00242-8","volume":"5","author":"Y Ni","year":"2021","unstructured":"Ni Y, Soliman A, Joehlin-Price A, Rose PG, Vlad A, Edwards RP, Mahdi H. High tgf-$$\\beta$$ signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition. NPJ precision oncology. 2021;5(1):101.","journal-title":"NPJ precision oncology"},{"issue":"7","key":"6125_CR43","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for rna-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):47\u201347.","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"6125_CR44","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/nar\/gkad347","volume":"51","author":"L Kolberg","year":"2023","unstructured":"Kolberg L, Raudvere U, Kuzmin I, Adler P, Vilo J, Peterson H. g: Profiler\u00e2\u20ac\u201dinteroperable web service for functional enrichment analysis and gene identifier mapping (2023 update). Nucleic Acids Res. 2023;51(W1):207\u201312.","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"6125_CR45","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/nar\/gkac194","volume":"50","author":"BT Sherman","year":"2022","unstructured":"Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, Imamichi T, Chang W. David: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022;50(W1):216\u201321.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"6125_CR46","doi-asserted-by":"publisher","first-page":"1163462","DOI":"10.1080\/2162402X.2016.1163462","volume":"5","author":"T Jiang","year":"2016","unstructured":"Jiang T, Zhou C, Ren S. Role of il-2 in cancer immunotherapy. Oncoimmunology. 2016;5(6):1163462.","journal-title":"Oncoimmunology"},{"key":"6125_CR47","doi-asserted-by":"publisher","first-page":"104539","DOI":"10.1016\/j.ebiom.2023.104539","volume":"90","author":"ME Raeber","year":"2023","unstructured":"Raeber ME, Sahin D, Karakus U, Boyman O. A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases. EBioMedicine. 2023;90:104539.","journal-title":"EBioMedicine"},{"issue":"1","key":"6125_CR48","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12943-023-01899-4","volume":"22","author":"X Wu","year":"2023","unstructured":"Wu X, Li T, Jiang R, Yang X, Guo H, Yang R. Targeting mhc-i molecules for cancer: function, mechanism, and therapeutic prospects. Mol Cancer. 2023;22(1):194.","journal-title":"Mol Cancer"}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-025-06125-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12859-025-06125-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-025-06125-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T10:03:18Z","timestamp":1746439398000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-025-06125-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6125"],"URL":"https:\/\/doi.org\/10.1186\/s12859-025-06125-0","relation":{},"ISSN":["1471-2105"],"issn-type":[{"value":"1471-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"119"}}